» Articles » PMID: 33302515

Cooperation and Interplay Between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer

Overview
Journal Cells
Publisher MDPI
Date 2020 Dec 11
PMID 33302515
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Epidermal growth factor receptor (EGFR) takes centre stage in carcinogenesis throughout its entire cellular trafficking odyssey. When loaded in extracellular vesicles (EVs), EGFR is one of the key proteins involved in the transfer of information between parental cancer and bystander cells in the tumour microenvironment. To hijack EVs, EGFR needs to play multiple signalling roles in the life cycle of EVs. The receptor is involved in the biogenesis of specific EV subpopulations, it signals as an active cargo, and it can influence the uptake of EVs by recipient cells. EGFR regulates its own inclusion in EVs through feedback loops during disease progression and in response to challenges such as hypoxia, epithelial-to-mesenchymal transition and drugs. Here, we highlight how the spatiotemporal rules that regulate EGFR intracellular function intersect with and influence different EV biogenesis pathways and discuss key regulatory features and interactions of this interplay. We also elaborate on outstanding questions relating to EGFR-driven EV biogenesis and available methods to explore them. This mechanistic understanding will be key to unravelling the functional consequences of direct anti-EGFR targeted and indirect EGFR-impacting cancer therapies on the secretion of pro-tumoural EVs and on their effects on drug resistance and microenvironment subversion.

Citing Articles

Exosome: an overview on enhanced biogenesis by small molecules.

Bavafa A, Izadpanahi M, Hosseini E, Hajinejad M, Abedi M, Forouzanfar F Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39862264 DOI: 10.1007/s00210-024-03762-9.


Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics.

Jackson Cullison S, Flemming J, Karagoz K, Wermuth P, Mahoney M J Extracell Biol. 2024; 3(11):e70017.

PMID: 39483807 PMC: 11522837. DOI: 10.1002/jex2.70017.


Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications.

Sun D, Chang H Tzu Chi Med J. 2024; 36(3):251-259.

PMID: 38993825 PMC: 11236075. DOI: 10.4103/tcmj.tcmj_28_24.


Extracellular Vesicles and Epidermal Growth Factor Receptor Activation: Interplay of Drivers in Cancer Progression.

Ferlizza E, Romaniello D, Borrelli F, Pagano F, Girone C, Gelfo V Cancers (Basel). 2023; 15(11).

PMID: 37296932 PMC: 10252121. DOI: 10.3390/cancers15112970.


Abscopal Effect, Extracellular Vesicles and Their Immunotherapeutic Potential in Cancer Treatment.

Salazar A, Chavarria V, Flores I, Ruiz S, la Cruz V, Sanchez-Garcia F Molecules. 2023; 28(9).

PMID: 37175226 PMC: 10180522. DOI: 10.3390/molecules28093816.


References
1.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y, Ngankeu A . EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011; 18(1):74-82. PMC: 3467100. DOI: 10.1038/nm.2577. View

2.
Toft D, Cryns V . Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2010; 25(2):199-211. PMC: 3035993. DOI: 10.1210/me.2010-0164. View

3.
Irannejad R, Tsvetanova N, Lobingier B, Von Zastrow M . Effects of endocytosis on receptor-mediated signaling. Curr Opin Cell Biol. 2015; 35:137-43. PMC: 4529812. DOI: 10.1016/j.ceb.2015.05.005. View

4.
Zanetti-Domingues L, Korovesis D, Needham S, Tynan C, Sagawa S, Roberts S . The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers. Nat Commun. 2018; 9(1):4325. PMC: 6193980. DOI: 10.1038/s41467-018-06632-0. View

5.
Tulchinsky E, Demidov O, Kriajevska M, Barlev N, Imyanitov E . EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2018; 1871(1):29-39. DOI: 10.1016/j.bbcan.2018.10.003. View